Table 2.

The clinicopathological characteristics between gastric cancer patients according to the expression of miR-1207-5p.

	Unchanged miR-1207-5p	Downregulated miR-1207-5p	Upregulated miR-1207-5p	P value
	n = 27	n = 2	n = 17
	n (%)	n (%)	n (%)
Age (y/o)				0.891
<65	9 (33.3)	1 (50)	6 (35.3)
≧65	18 (66.7)	1 (50)	11 (64.7)
Gender				0.890
M/F	16/11	1/1	11/6
Tumor size (cm)				0.986
<5	14 (51.9)	1 (50)	10 (58.8)
≧5	13 (48.1)	1 (50)	7 (41.2)
Tumor location				0.421
Upper third stomach	4 (14.8)	0	4 (23.5)
Middle third stomach	10 (37)	2 (100)	7 (41.2)
Lower third stomach	13 (48.1)	0	6 (35.3)
Lauren's classification				0.061
Intestinal type	14 (51.9)	0	13 (76.5)
Diffuse type	13 (48.1)	2 (100)	4 (23.5)
Cell differentiation				0.100
Poor	14 (51.9)	2 (100)	5 (29.4)
Moderate/well	13 (48.1)	0	12 (70.6)
Stromal reaction type				0.013
Medullary	1 (3.7)	1 (50)	5 (29.4)
Intermediate	21 (77.8)	0	12 (70.6)
Scirrhous	5 (18.5)	1 (50)	0
Lymphovascular invasion				0.006
Absence	9 (33.3)	1 (50)	13 (76.5)
Presence	18 (66.7)	1 (50)	4 (23.5)
Pathological T categories				0.005
T1	1 (3.7)	1 (50)	10 (58.8)
T2	9 (33.3)	0	3 (17.6)
T3	14 (51.9)	1 (50)	4 (23.5)
T4	3 (11.1)	0	0
Pathological N categories				0.005
N0	7 (25.9)	1 (50)	14 (82.4)
N1	7 (25.9)	0	0
N2	6 (22.3)	0	2 (11.8)
N3	7 (25.9)	1 (50)	1 (5.9)
Pathological TNM stage				0.002
I	6 (22.2)	1 (50)	12 (70.6)
II	10 (37)	0	4 (23.5)
III	6 (22.2)	0	1 (15.2)
IV	5 (18.6)	1 (50)	0